2023
Association Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy
Voruganti T, Soulos P, Mamtani R, Presley C, Gross C. Association Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy. JAMA Oncology 2023, 9: 334-341. PMID: 36701150, PMCID: PMC9880865, DOI: 10.1001/jamaoncol.2022.6901.Peer-Reviewed Original ResearchConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerImmune checkpoint inhibitorsUse of ICIsPatients 75 yearsCell lung cancerDrug Administration approvalCohort studyOlder patientsLung cancerAdministration approvalUS FoodAdoption of immunotherapyMedian overall survivalCancer-directed therapySubstantial survival benefitFirst US FoodCheckpoint inhibitorsStage IIIBClinical characteristicsICI useMedian survivalOverall survivalSurvival benefitSurvival gain
2021
Patient- and provider-level predictors of mortality among patients with metastatic renal cell carcinoma receiving oral anticancer agents.
Spees L, Dinan M, Jackson B, Baggett C, Wilson L, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Wheeler S. Patient- and provider-level predictors of mortality among patients with metastatic renal cell carcinoma receiving oral anticancer agents. Journal Of Clinical Oncology 2021, 39: 116-116. DOI: 10.1200/jco.2020.39.28_suppl.116.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anti-cancer agentsPatients' clinical characteristicsProvider-level factorsCause mortalityRenal cell carcinomaClinical characteristicsHazard ratioMetastatic diagnosisCell carcinomaState cancer registry dataCox proportional hazards modelProvider-level predictorsLower overall survivalOral anticancer agentsCancer registry dataReal-world populationProportional hazards modelSkilled nursing facilitiesProvider Enumeration SystemAnti-cancer agentsIndex dateOverall survivalPatient demographicsBlack patients
2017
Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study.
Davis BA, Aminawung JA, Abu-Khalaf MM, Evans SB, Su K, Mehta R, Wang SY, Gross CP. Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study. Journal Of The National Comprehensive Cancer Network 2017, 15: 346-354. PMID: 28275035, DOI: 10.6004/jnccn.2017.0034.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorBreast NeoplasmsConnecticutFemaleGene Expression ProfilingGenetic TestingHealth Services AccessibilityHealthcare DisparitiesHumansLymphatic MetastasisMiddle AgedNeoplasm GradingNeoplasm StagingOdds RatioPatient Outcome AssessmentPopulation SurveillanceRegistriesRetrospective StudiesSocioeconomic FactorsYoung AdultConceptsPopulation-based studyOncotype DXODX testingBreast cancerHispanic womenHormone receptor-positive breast cancerReceptor-positive breast cancerRetrospective population-based studyWhite womenRacial disparitiesGEP test resultsBreast cancer careBreast cancer outcomesStudy inclusion criteriaGene expression profiling testsMore white womenClinical characteristicsTest receiptCancer outcomesCancer careInclusion criteriaLogistic analysisEthnic disparitiesStatewide populationWomen
2012
Short-term complications and use of breast brachytherapy in the national Medicare population in 2008-2009.
Presley C, Soulos P, Herrin J, Roberts K, Yu J, Killelea B, Lesnikoski B, Long J, Gross C. Short-term complications and use of breast brachytherapy in the national Medicare population in 2008-2009. Journal Of Clinical Oncology 2012, 30: 1030-1030. DOI: 10.1200/jco.2012.30.15_suppl.1030.Peer-Reviewed Original ResearchWhole breast irradiationHospital referral regionsBone complicationsClinical characteristicsSkin complicationsReferral regionsEarly-stage breast cancerNational treatment patternsOne-year overallReceipt of chemotherapyNumber of comorbiditiesShort-term complicationsDeep tissuesNational Medicare populationAdjuvant radiationComplication rateTreatment patternsDiagnosis codesBreast cancerMedicare claimsMedicare populationComplicationsMedicare beneficiariesTreatment groupsClinical practice